surpass-cvot tirzepatide 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Read now: The SURPASS-EARLY trial

it makes managing my weight feel more achievable." Key Insight: Combining therapy with structured monitoring and ongoing discussion ensures safe, effective, and sustainable weight management, while keeping the patient engaged, informed, and motivated throughout the process

It is being explored for immune modulation, chronic infections, viral support, immune resilience, inflammation balance, and complex chronic illness

A 2025 network meta-analysis put lean mass at roughly a quarter of total weight reduction for both semaglutide and tirzepatide, which is similar to what happens with any weight loss

This molecule forms when a naturally occurring peptide known as GHK binds with a copper ion, creating a complex that has been widely studied in relation to skin biology and tissue signaling